Vermillion Wealth Management’s Moderna MRNA Stock Holding History

Vermillion Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25	Closed	-$1.27K	–	2107
2026 Q1	$1.27K	Buy	+25	New	+$1.17K	﹤0.01%	763

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Vermillion Wealth Management's MRNA Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 25 shares — an estimated $1.27K sold.

Vermillion Wealth Management first reported a position in MRNA in Q1 2026 and held it in 1 quarter. The position peaked at $1.27K in Q1 2026. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Vermillion Wealth Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Vermillion Wealth Management sold 25 Moderna shares in Q2 2026, an estimated $1.27K.
Vermillion Wealth Management first reported a position in Moderna in Q1 2026 and held it in 1 quarter.
Vermillion Wealth Management's Moderna position peaked at $1.27K in Q1 2026.
775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.